Macrophage-Specific Chemokines Induced via Innate Immunity by Amino Acid Copolymers and Their Role in EAE by Kovalchin, Joseph et al.
Macrophage-Specific Chemokines Induced via Innate
Immunity by Amino Acid Copolymers and Their Role in
EAE
Joseph Kovalchin
1, Jeffrey Krieger
1, Michelle Genova
1, Norio Kawamoto
2, Michael Augustyniak
1,
Kathryn Collins
1, Troy Bloom
1, Allyson Masci
1, Tara Hittinger
1, Ingrid Dufour
1, Jack L. Strominger
2*, Eric
Zanelli
1
1Peptimmune, Inc., Cambridge, Massachusetts, United States of America, 2Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge,
Massachusetts, United States of America
Abstract
The random amino acid copolymer poly(Y,E,A,K)n (CopaxoneH) is widely used in multiple sclerosis treatment and a second
generation copolymer poly(Y,F,A,K)n with enhanced efficacy in experimental autoimmune encephalomyelitis in mice has
been described. A major mechanism through which copolymers function to ameliorate disease is the generation of
immunosuppressive IL-10-secreting regulatory T cells entering the CNS. In addition, the antigen presenting cell to which
these copolymers bind through MHC Class II proteins may have an important role. Here, both CCL22 (a Th2 cell
chemoattractant) in large amounts and CXCL13 in much smaller amounts are shown to be secreted after administration of
YFAK to mice and to a smaller extent by YEAK parallel to their serum concentrations. Moreover, bone marrow-derived
macrophages secrete CCL22 in vitro in response to YFAK and to higher concentrations of YEAK. Strikingly, these chemokines
are also secreted into serum of MHC Class II 2/2 mice, indicating that an innate immune receptor on these cells also has an
important role. Thus, both the innate and the adaptive immune systems are involved in the mechanism of EAE amelioration
by YFAK. The enhanced ability of YFAK to stimulate the innate immune system may account for its enhanced efficacy in EAE
treatment.
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Introduction
Two random amino acid copolymers have been described, the
administration of which ameliorates experimental autoimmune
encephalomyelitis (EAE) and several other autoimmune diseases in
mice and other rodents using several different models. They are
poly(Y,E,A,K)n (called YEAK, CopaxoneH, glatiramer acetate,
Copolymer-1) [1,2] and poly(Y,F,A,K)n (called YFAK) [3]. In
these models, YFAK is far more effective than YEAK [4,5,6,7].
YEAK (CopaxoneH) has been in clinical use for several decades for
the treatment of multiple sclerosis (MS) although its usefulness in
this disease is limited to a ,30% reduction in frequency of
relapses. YFAK has gone through Phase Ia and Ib clinical trials
(the latter in patients with secondary progressive MS) with no sign
of toxicity [8,9] and is ready for a Phase II trial in patients with
relapsing, remitting MS.
Both copolymers have been thought to exert their primary
immunosuppressive action through the generation of immunosup-
pressive T cells that secrete IL-10 as a major immunomodulatory
cytokine, as well as other cytokines [6]. Over the years, however, a
number of papers have appeared indicating that the antigen
presenting cell, defined as either a dendritic cell or a macrophage, is
alsomodifiedbycopolymertreatmentand thatitplaysanimportant
role in the disease process [10–13]. In addition, IL-10 secreting B
cells have been reported to be produced as a result of YEAK
treatment [14].
The purpose of the present study was to define further the
nature of the antigen presenting cell modified by copolymer
treatment and its relationship to the IL-10 secreting T cells that
have been described previously.
Methods
Amino Acid Copolymers YFAK and YEAK
YFAK is a mixture of random-sequence peptides composed of
the amino acids L-tyrosine, L-phenylalanine, L-alanine, and L-
lysine in the approximate molar ratios of 1.0: 1.3: 24.0: 6.0,
respectively. YFAK is manufactured by solid phase synthesis on
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amino acid derivatives and coupling reagents are removed by
filtration. YFAK is cleaved, N-acetylated, precipitated, washed
and dried under vacuum. YEAK (CopaxoneH, purchased from
Hanna Pharmaceuticals (Wilmington, DE)) was stored at 4uCa ta
concentration of 20 mg/mL according to the manufacturer’s
package insert. YFAK or YEAK was diluted in 42 mg/mL
mannitol (Sigma, St. Louis, MO) in water at concentrations
indicated. Compounds were administered s.c. (subcutaneously)
interscapularly at a dose volume of 100 mL/10 g body weight.
Pharmacokinetic Assays for YFAK and YEAK
All mouse work herein discussed was performed under an
approved protocol with the review of Harvard University’s
Standing Committee on the Use of Animals in Research and
Teaching, under the Guidelines for the Use of Vertebrate Animals
in Research and Teaching of the Faculty of Arts and Sci-ences of
Harvard University, and under the NIH Guide for the Care and
Use of Laboratory Animals. Ameliorative steps were taken
whenever animals were injected or observed in disease states
including the administration of anesthesia, food supplementation,
and temperature modification. The HU/FAS animal care and use
program maintains full AAALAC accreditation, is assured with
OLAW (A3593-01), and is currently registered with the USDA.
This work was carried out under Protocol 99-01, ap-proved in
latest amendment by IACUC on 05/13/11.
The pharmacokinetic (PK) assays (validated in CD-1 male mice
obtained from Avogadro, Fontenilles, France and bred at Charles
River Laboratories, Wilmington, MA) for YFAK and YEAK are
direct competition ELISAs [8]. Briefly, YFAK or YEAK are
immobilized on a 96-well microtiter plate overnight at 4uC, then
blocked for two hours with 300 mL per well of PBS/10% FBS, and
washed three times with 300 mL per well of PBS/0.05% Tween 20
using a plate washer. Mouse serum containing known or unknown
concentrations of YFAK/YEAK were added to the washed plates
along with purified biotinylated anti-YFAK/YEAK antibodies
and Protein A and incubated for 2 hours on a plate shaker.
Unbound material was washed away and diluted streptavidin-
HRP conjugate added to the wells and incubated for 1 hour. After
washing, substrate (TMB from BD Biosciences–Pharmingen, San
Diego, CA) was added and circulation continued for 15 minutes,
yielding a blue color that turns yellow when stop solution (2N
H2SO4) is added. The optical density was measured at 450 nm,
and a standard curve generated. The intensity of the color
measured is proportional to the amount of biotinylated anti-
YFAK/YEAK antibody bound by the immobilized YFAK/
YEAK.
YFAK/YEAK biotinylated antibodies were Protein A purified
from rabbit polyclonal antiserum generated against the appropri-
ate antigen. Briefly, rabbits were immunized with YFAK or
YEAK. The rabbit polyclonal antiserum was diluted 1:1 with
pH 8.0 buffer, added to a Protein A column (column was
equilibrated with the pH 8.0 buffer), incubated one hour at room
temperature, then the unbound proteins were washed off the
column with the pH 8.0 buffer. The specific antibody was eluted
with pH 2.8 buffer, dialyzed against PBS at 4uC overnight and the
protein concentration was determined using Coomassie blue. The
dialyzed antibody was then incubated two hours at room
temperature with a ten molar excess of biotin and dialyzed against
PBS at 4uC overnight. The dialyzed biotinylated antibody was
concentrated using a desalting column and the protein concen-
tration was determined using Coomassie. The mole-to-mole ratio
of biotin to protein was determined using the HABA method
(Pierce Biotechnology, Rockford, IL).
In Vivo Serum/Plasma Collection
Male CD-1 mice (Charles River Laboratories) at 8–12 weeks of
age, female SJL mice (Charles River Laboratories) at 7–9 weeks of
age, and MHC II 2/2 mice (B6.SJL(129)-Ptprc
a/BoyAiTac H2-
Ab1
tm1Gru N7+N6) and their wild type control littermates
(Taconic Farms, Hudson, NY) at 8–11 weeks of age were used
for PK and chemokine release experiments. Mice were dosed s.c.
interscapularly as indicated using a 27 gauge needle for each
experiment. Whole blood was collected by cardiac puncture with a
25 gauge needle and 1 mL syringe into tubes which do not contain
anti-coagulant (yellow topped VacutainerH tubes with serum
separator). The blood sample was allowed to clot at room
temperature for 15–30 minutes and then was centrifuged at 4uC,
10,000 RPM, for 10 minutes in order to isolate serum. Whole
blood was also collected into tubes containing anti-coagulant
(purple topped VacutainerH tubes with EDTA) for plasma
preparation. Blood was collected, inverted several times, and then
centrifuged at 4uC, 10,000 RPM, for 10 minutes. Both serum and
plasma were collected, placed on dry ice, and then stored at
280uC until further analysis.
In Vitro Bioassay Using Cells of the RAW 264.7
Macrophage Cell Line
RAW264.7 cells (ATCC, Manassas, VA) were plated in 96 well
U-bottom tissue culture plates at 5610
5 cells per well with and
without compounds incubated in 200 ml culture medium (10%FBS
(ThermoScientific-Hyclone,Waltham,MA)/ DMEMwith1%PSG
(Invitrogen-Gibco, Carlsbad, CA)) for 24 hours at 37uCw i t h5 %
CO2 in a humidified environment. Cell-free culture supernatant was
collected and immediately frozen at 280uC for future testing with a
commercial CCL22 ELISA kit following manufacturer’s protocol
(R&D Systems, Minneapolis, MN).
In Vitro Bone Marrow Cultures
Femurs were excised and bone marrow cells were collected from
twenty-five naı ¨ve female SJL mice (Charles River Laboratories; 9–
12 weeks of age) by snipping off the ends and flushing the marrow
with HL-1 media (Lonza-Biowhittaker, Walkersville, MD) using a
1 mL syringe equipped with a 30 gauge needle. Single-cell
suspensions from femur-derived bone marrow cells were depleted
of T and B cells by negative selection using a combination of
CD90.2 and CD19 magnetic beads with the method described in
the manufacturer’s package insert (Miltenyi Biotec, Auburn, CA).
The residual cells, which are enriched for myeloid progenitors,
were re-suspended and plated at 1610
6 cells per well to 24 well
tissue culture plates in 2 mL CM
+ media, defined as HL-1 media
containing 10 mM HEPES (Invitrogen-Gibco), 1 mM Sodium
Pyruvate (Invitrogen-Gibco), 2 mM L-glutamine (Invitrogen-
Gibco), 1% Penicillin/Streptomycin/L-glutamine (Invitrogen-
Gibco), 1% nonessential amino acids (NEAA) (Invitrogen-Gibco),
and 50 mM 2-Mercaptoethanol (Sigma)) supplemented with 10%
FBS (Thermo Scientific-Hyclone), 10 ng/mL IL-3 (R&D Sys-
tems), and 2.5 ng/mL TNF-a (R&D Systems) to obtain bone
marrow –derived macrophages [18] in addition to equimolar
concentrations (1.5, 3, 6, and 12 mM) of YFAK, YEAK, or the
encephalatogenic peptide PLP139–151 (A&A Labs). The cells
were cultured for six days in a humidified 37uC incubator with 5%
CO2. On day 7, half of the medium was removed from each well
and the cells were then treated with an equivalent volume of LPS
(Sigma, St. Louis, MO) at a final concentration 1 mg/mL, without
additional YFAK, YEAK, or PLP139–151 peptide, for two days.
On study day 9, cell-free culture supernatants were harvested,
aliquoted, and immediately frozen at 280uC. After collection of
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San Jose, CA) were trimmed to fit into the wells of the 24 well
tissue culture plates, and cells from in vitro bone marrow cultures
were collected by scraping. Cell viability was tested using trypan
blue exclusion. Cell viability was shown to be 92.160.5% (mean 6
SEM) (data not shown).
Flow Cytometric Analysis of In Vitro Bone Marrow
Cultures
Bone marrow cells were analyzed by flow cytometry on day 1,
both pre- and post- depletion, and on day 9. At each day, cells
were washed twice in staining buffer containing 2% FBS and
0.09% sodium azide at pH 7.4 (BD Pharmingen, San Diego, CA).
To decrease non-specific cell staining, Fc receptors were blocked
by incubating cells for 5 minutes on ice with an optimal
concentration of rat anti-mouse CD16/CD32 (BD Pharmingen)
diluted in staining buffer. Cells were then stained for 30 minutes
on ice in the dark by the addition of an antibody conjugate panel
selected to enable the phenotypic analysis of monocytes and to
confirm the absence of T and B cells (F4/80: FITC- eBioscience,
San Diego, CA, and the remainder from BD Pharmingen: B220:
PE-, CD11b: PerCP-Cy5.5-, CD11c: PE-Cy7-, CD3: APC-, and
GR-1: APC-Cy7). After staining, cells were washed twice with
staining buffer, then red blood cells (RBC) were lysed and cells
were fixed (FACS Lyse, BD Pharmingen) on day 1, or cells were
fixed without lysis (CytoFix, BD Pharmingen) on day 9. Following
2 washes with staining buffer, cells were resuspended to staining
buffer and acquired on a Becton Dickinson FACS CANTO II flow
cytometer with FACSDiva software.
Evaluation of Cytokines and Chemokines From In Vitro
Bone Marrow Cultures and In Vivo Assays
Cell-free culture supernatants, EDTA plasma, and serum
samples were sent to Rules-Based Medicine (Austin, TX) for
analysis of cytokine and chemokine production using their Rodent
Multi-Analyte Profiling (MAP) Version 1.6. EDTA plasma
samples were also tested for CCL22 and CXCL13 and the cell-
free culture supernatants for CCL22, CXCL13, and TNF-a using
commercially available ELISA kits following manufacturer’s
protocol (R&D Systems). For IL-3 analysis, female SJL mice were
dosed daily for 5 days with 0.25, 2.5, or 25 mg/kg of YFAK or
YEAK. Spleens were collected after a one week resting period.
Splenocytes were re-stimulated for 3 days with 5 mg/mL of
corresponding copolymer after which cell culture supernatants
were harvested and tested for IL-3 secretion using commercially
available ELISA kits following the manufacturer’s protocol (R&D
Systems).
Results
Copolymer plasma levels and release of the macrophage-
specific chemokines CCL22 and CXCL13 in vivo induced
by copolymers
Recently, a role for myeloid cells, as well as IL-10-secreting T
cells, in the protective response to amino acid copolymers has been
demonstrated as the ability of YEAK to stimulate macrophages,
termed ‘‘M2 regulatory macrophages,’’ that on adaptive transfer
decreased disease severity [13]. To address this question further
and to define the nature of the macrophages produced, first
pharmacokinetic (PK) assays to quantify YFAK or YEAK in serum
were developed [8]. Assays for the presence of these copolymers in
serum were carried out in CD-1 male mice because they are larger
(,35 grams) than SJL mice (,20 grams), making it possible to
obtain sufficient serum/plasma from a single mouse to test both for
copolymers and for substances released in the same sample. Male
CD-1 mice were dosed once s.c. with Vehicle (42 mg/L mannitol in
H2O), 25 mg/kg YFAK in mannitol, or 25 mg/kg YEAK in
mannitol. Serum concentrations over an 8-hour time course were
analyzed (Figure 1A). The high dose of 25 mg/kg was used in order
to amplify the response, allowing the kinetics of the copolymer to be
followed. Serum concentrations of YFAK were significantly greater
than those of YEAK for alltime points between 15 and 120 minutes
post administration. Mice receiving YFAK peaked at 2,6806
613 ng/mL at 30 minutes while those receiving YEAK peaked at
only 8266414 ng/mL at 8 minutes. Thus, YFAK reached a higher
Cmax slower than YEAK and remained in circulation much longer
than YEAK. Additional PK profiles showed that a significant linear
correlation, tested in the range of 0–$80 mg/kg amino acid
copolymers, existed between the s.c. dose administered and the
mean serum Cmax. At the low dose of 2.5 mg/kg (50 mg to a 20 g
mouse),theefficaciousdoseinEAE,YFAKwas atorbelowthelevel
of detection for the current PKassay. A significant linearcorrelation
was also found between the s.c. dose and the total systemic
exposure, as defined by the area under the curve (AUC) for the
serum concentration of YFAK and YEAK for the entire time
course. The PK assay that was developed is sensitive enough not
only to identify the full length YFAK (52 a.a., MW 4500) or YEAK
(,70 a.a. average, MW 7500) but also to detect sub-fragments
($30mers) which may occur as a result of peptidase digestion and
may be biologically active.
Evidence of macrophage activation through the release of M2
chemokines [15] was then sought. Within minutes after s.c.
administration and detection of the copolymer in plasma, in
parallel two substances appeared prominently in mouse plasma
following in vivo administration of both copolymers, viz. CCL22
(originally called MDC, macrophage-derived chemokine) and
CXCL13 (BLC, B lymphocyte chemokine). Greater transient
increases in CCL22 and CXCL13 plasma concentrations were
observed in mice dosed with YFAK as compared to those dosed
with YEAK. Mice receiving YFAK reached a peak of 6176
80 pg/mL for plasma CCL22 at 30 minutes compared to mice
receiving YEAK that peaked at 320626 pg/mL of CCL22 at
8 minutes (Figure 1B). Increased CXCL13 plasma concentrations
were also detected within minutes after YFAK administration s.c.
(Figure 1C), reaching a maximum plasma concentration of
1,1606210 pg/mL at 60 minutes post administration. Plasma
CXCL13 in mice dosed with YEAK peaked at 8166188 pg/mL
at 30 minutes but was not significantly greater than the vehicle
control. A significant linear correlation existed between the serum
concentration of YFAK and the plasma concentration of CCL22
and CXCL13. Similar, though less complete, data were also
obtained in SJL mice (data not shown).
Role of innate immune system in chemokine
release. Since binding of amino acid copolymers to MHC
class II molecules has been considered to be central to their
mechanism of action [16,17], it was important to investigate
whether or not the induced release of chemokines by YFAK or
YEAK was a MHC Class II protein (MHC II) dependent
response. However, no differences in chemokine release into
plasma were observed in MHC II deficient mice (I-Ab knockout in
the B6/SJL background that does not express I-E, see Methods)
compared to B6/SJL congenic controls. YFAK and YEAK
significantly increased CCL22 production compared to vehicle
treatment in both strains of mice (Figure 2A). YFAK also
significantly increased CXCL13 production in both strains of
mice while again YEAK had no effect on CXCL13 plasma level in
either strain (Figure 2B). The release of CCL22 and CXCL13 by
Macrophage Stimulation by Amino Acid Copolymers
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immune receptor(s) present on myeloid cells is (are) capable of
interacting with YFAK and YEAK to mediate the secretion of
these chemokines.
Secretion of CCL22 from RAW 264.7 Cells Induced by the
YFAK and YEAK Copolymers and by YFAK Oligomers. A
similar phenomenon was observed in vitro when YFAK was tested
on the differentiated mouse macrophage line RAW 264.7. These
cells secreted CCL22 in increasing amounts at increasing
concentrations of copolymers, reaching a plateau at ,20 mM
YFAK (MW 4500) or ,40 mM YFAK (MW 7300) (Figure 3A).
The availability of an unlimited number of cells of this cell line also
made possible examination of the effects of copolymer size on the
release of CCL22. Truncated fragments of the YFAK 52-mer
(MW 4,500), 10mer (MW 1,114), 20mer (MW 1,890), 30mer (MW
2,751), and 40mer (MW 3,534) were isolated during the course of
copolymer manufacturing. The release of CCL22 was essentially
linear with the length (Figure 3B). Neither the copolymers nor LPS
induced secretion of CXCL13 from RAW 264.7 cells.
Chemokine and Cytokine Production In Vitro by Bone
Marrow Derived Cells. Next, bone marrow derived myeloid
cells [15,18] were employed to analyze in vitro the secretion of the
two monocyte-derived chemokines CCL22 and CXCL13
associated with immunoregulation. In brief, myeloid progenitors
prepared from bone marrow cells of SJL mice (see Methods) were
incubated for six days in medium containing 10 ng/ml IL-3,
2.5 ng/ml TNFa, and equimolar concentrations of YFAK or
YEAK at 0, 1.5, 3, 6, and 12 mM followed by 2 further days
incubation with 1 mg/ml LPS. IL-3 has been shown to induce M2
macrophage differentiation in bone marrow myeloid progenitors
[18]. These concentrations of copolymers are in the range of those
that would be obtained in vivo after the administration of the
therapeutic dose of 50 mg to SJL mice. Phenotyping of the resulting
myeloid cell population indicated a marked increase of CD11b+
F4/80
neg-low cells with a corresponding decrease in CD11b
+ F4/
80
high cells in mice treated with YFAK (Figure S1). Similarly, the
frequency of CD11b
+ Gr-1
high cells increased while that of CD11b
+
Gr-1
mid decreased in the myeloid cells of YFAK-treated mice
(Figure S2).Nochangeineithercellpopulationwasfoundincontrol
PLP 139–151-treated mice or in those treated with YEAK.
CD11b
+F4/80
neg-low Gr-1
high cells seen after treatment with YFAK
are phenotypically an immature macrophage population, possibly in
the myeloid suppressor lineage [19].
These myeloid cells secreted a very high baseline level of
CCL22 (26,400 pg/ml), but incubation with YFAK, and less
effectively YEAK, induced much higher dose dependent levels
peaking at 45,200 pg/ml for YFAK at 6 mM and at 52,500 pg/ml
for YEAK at 12 mM (Figure 4A). The decrease of CCL22 as seen
at 12 mM was paralleled by a decrease of IL-4 and IL-13 secretion
by T cells at this extremely high level in clinical studies [9], and
has also been observed in additional studies of myeloid cells
differentiated in the presence of GM-CSF that secrete CCL22
upon stimulation with YFAK (N.K., unpublished observation).
After treatment of the myeloid cells with YFAK, the
concentration of CXCL13 secreted increased to 671651 pg/
mL, while treatment with YEAK or PLP139–151 resulted in no
change from the baseline level of ,20 pg/mL (Figure 4B).
The effects of YFAK and YEAK on supernatant concentration
of CXCL1 and CXCL2 that are associated with neutrophil
chemotaxis were also examined. Reciprocally, the concentra-
tion of CXCL1 and CXCL2 fell from baseline levels of
5,2256165 pg/mL or 9,1936385 pg/mL respectively to near 0
in both cases while little or no change was observed with YEAK or
PLP139–151 (Figure 4C and D).
The concentration of the pro-inflammatory cytokines TNF-a,
IL-6, and IL12p70 were all substantially decreased by YFAK, but
not by YEAK or PLP139–151 (Figure 4E, F, G). This latter
observation contrasts with previous work demonstrating the
capacity of YEAK to inhibit TNF-a production by THP-1
macrophages stimulated with LPS and IFN-c [20]. PLP 139–151
had little or no effect on concentrations of IL-6 or IL-12p70 and
slightly increased the concentrations of TNF-a (Figure 4E, F, G).
These assays were carried out either using the Rules-Based
Medicine Rodent MAP version 1.6 panel that examines 69
Figure 1. Kinetics of serum copolymer and of plasma
chemokine levels after administration of YFAK or YEAK. Data
are shown as mean 6 SEM from an experiment in which 3–4 mice were
euthanized and samples collected at each time point. (A) Serum YFAK
(ng/mL) is significantly greater than YEAK (ng/mL) at multiple time
points from 15 to 120 minutes. (B, C) YFAK induced increased plasma
CCL22 (pg/mL) and CXCL13 (pg/mL) levels when compared to YEAK as
shown. Significance was calculated using an unpaired t-test: YFAK vs.
YEAK or Control * p#0.05, ** p#0.01.
doi:10.1371/journal.pone.0026274.g001
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ELISA. No significant secretion beyond that of the medium
controls was observed for any of the other chemokines or cytokines
in the panel on stimulation with YFAK, YEAK, or PLP139–151
(an additional control) in the range of 1.5–12 mM (with the
exception of CCL9 – see Discussion). Notable was the absence of
induced secretion of IL-10 from the myeloid cells beyond the low
level of 1270 pg/ml found in the medium control.
Figure 2. Copolymer-mediated induction of CCL22 and CXCL13 in MHC Class II KO mice. Female MHC Class II deficient mice and their
littermate controls (n=9–10) were administered one subcutaneous dose of 50 mg/kg YFAK, 50 mg/kg YEAK, or Vehicle Control. Blood was collected
and plasma was prepared 30 minutes post administration and tested for CCL22 (A) and CXCL13 (B). Data is shown as mean (pg/mL) 6 SEM.
Significance was calculated using an unpaired t-test: YFAK or YEAK vs. Vehicle Control + p#0.05; ++p#0.01; +++p#0.001; ++++p#0.0001; YFAK
vs. YEAK * p#0.05; ** p#0.01.
doi:10.1371/journal.pone.0026274.g002
Figure 3. CCL22 secretion induced from the RAW 264.7 macrophage cell line. (A) RAW264.7 cells were plated on 96 well U-bottom tissue
culture plates at 56105 cells per well and incubated in culture medium (10% FBS/DMEM with 1% PSG) without or with molar equivalent
concentrations of copolymers for 24 hours at 37uC with 5% CO2 in triplicate. Cell-free culture supernatant was collected and immediately frozen at
280uC for testing using a commercial CCL22 ELISA kit. Data are represented as a non-linear regression curve fit and shown as mean (pg/mL) 6 SEM.
(B) Linear correlation be-tween area under the curve of CCL22 production and the length/molecular weight (Da) in the culture supernatants of
RAW264.7 cells incubated in culture medium with YEAK, YFAK, or molar equivalent of truncated YFAK (r2=0.9637, p,0.0001.
doi:10.1371/journal.pone.0026274.g003
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of Mice Treated with YFAK or YEAK. Since both YFAK and
YEAK stimulate splenocytes and spleen-derived T cell lines to
secrete TH2 cytokines including IL-10, IL-13, and IL-4, the latter
two of which have been reported to induce M2 macrophage
differentiation [15], the question arose whether the macrophage-
stimulating IL-3, a T cell cytokine, was also produced. Moreover,
this cytokine had been added to the culture conditions used to
differentiate bone-marrow cells into macrophages in the presence
of YEAK or YFAK (Figure 4 and Figure S1, S2).
To answer this question, female SJL mice were dosed daily for 5
days with 0.25, 2.5, or 25 mg/kg of YFAK or YEAK. Spleens were
collected after a one week resting period. Splenocytes were re-
stimulated for 3 dayswith5 mg/mLofcorresponding copolymer after
which cell culture supernatants were harvested and tested for IL-3
secretion. Splenocytes from mice treated with 0.25 mg/kg of YEAK
or YFAK produced the greatest concentrations of IL-3 (Figure 5). As
the dose of YFAK or YEAK increased, levels of IL-3 decreased. No
significant difference in the release of IL-3 in splenocytes stimulated
with comparable doses of YFAK or YEAK was observed.
Figure 4. Effects of YFAK and YEAK on chemokine and cytokine secretion from bone marrow-derived myeloid cells. Cytokine and
chemokine production was analyzed from bone marrow-derived myeloid cells (BMMC). Data are from a representative experiment in which samples
were run in 4 replicates and are shown as mean (pg/mL) 6 SEM. In vitro compound concentrations administered were 1.5, 3.0, 6.0, and 12.0 mM.
Significance was calculated using an unpaired t-test: YFAK vs. YEAK * p#0.05, ** p#0.01, *** p#0.001, **** p#0.0001.
doi:10.1371/journal.pone.0026274.g004
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Since the approval of the random amino acid copolymer YEAK
(CopaxoneH) for the treatment of RR-MS, YFAK, a second
generation copolymer with enhanced efficacy in mouse models of
EAE has been described. Understanding the mechanism of action
of the copolymers has engaged numerous laboratories (reviewed
by [13,21–22]). Here, YFAK and YEAK are shown to have
dramatically different effects on the immune system in mice,
especially with respect to effects on the innate immune response
that plays an important role in efficacy. The major molecular
differences between YFAK and YEAK are highlighted in Table 1.
YFAK is a solid phase synthesized acetylated 52mer random
copolymer (relative ratio: Tyrosine 1.0, Phenylalanine 1.2, Alanine
23.5, and Lysine 6.0) that has a strong net positive charge. YEAK,
on the other hand, is a solution phase synthesized non-acetylated
20–200mer random copolymer (relative ratio: Tyrosine 3.5,
Glutamic Acid 1.5, Alanine 4.5, and Lysine 3.6) that has a slightly
net positive charge. YFAK is significantly more efficacious than
YEAK in the prophylaxis of the induction of EAE or in the
treatment of established EAE in mice ([4,5], and further
documented in more detail in Figure S3).
The serum levels reached in mice after s.c. administration
(measured using a newly developed antibody-based method) of
YFAK and its duration were much larger than those for YEAK
(Figure 1). In spite of its peptidic nature, YFAK (and sub-
fragments $30-mers) were detectable in mouse serum for several
hours. YFAK may be binding to a plasma component that
prevents its rapid degradation by peptidases, possibly a function of
its strong net positive charge when compared to YEAK.
Acetylation of YFAK on the N-terminus also may help protect it
from peptidase degradation. A significant linear correlation was
observed between the mean serum concentration of YFAK or
YEAK (Cmax) and the administered s.c. dose.
The detection of YFAK and YEAK in the serum coincided with
the appearance in plasma of CCL22 and CXCL13 within minutes
of copolymer administration (Figure 1). These chemokines are
known to be secreted by regulatory M2a and M2c macrophages,
respectively [15], also known as alternatively activated macro-
phages [23]. YFAK induced a significantly higher Cmax for
CCL22 and CXCL13 than YEAK. Production of CCL22 and
CXCL13 induced by both copolymers was independent of MHC
class II as shown by their secretion in the MHC Class II2/2 mice
(Figure 2). A second innate immune receptor for these peptide
copolymers, in addition to MHC Class II, must be functional.
Systemic exposure to copolymers may be important to insure a
broad effect on the innate immune system. The enhanced efficacy
of YFAK in mice may be related to its intrinsic action on myeloid
cells and the enhanced time of serum availability. Although the
effects of YFAK and YEAK on plasma CCL22 and CXCL13
during induction of EAE and its therapy was not measured in
these experiments, the analysis of serum CCL22 during admin-
istration of YFAK to patients with secondary progressive multiple
sclerosis in a Phase Ib clinical trial was carried out and the
appropriate elevation was observed [9].
Myeloid progenitors differentiated to macrophages in vitro in the
presence of IL-3, as well as the macrophage cell line RAW264.7,
were also shown to secrete CCL22 in response to YFAK and to
YEAK at high concentrations (Figures 3 and 4). Moreover, splenic
T cells induced by YFAK also secrete IL-3 (Figure 5), as well as the
M2 macrophage differentiating cytokines IL 4 and IL-13. IL-3 is a
cytokine that stimulates development of multiple lineages of
hematopoietic cells including myeloid macrophages and neutro-
phils, but excluding lymphoid cells. These data lead to the
hypothesis summarized in Figure 6 that an important role of
regulatory macrophages stimulated by amino acid copolymers is to
secrete the chemokine CCL22 that attracts T cells, leading to
increased numbers of IL-10-secreting T cells. Whether this
phenomenon results from expansion of a small, preexisting pool
of these cells or whether the regulatory macrophages induce
naı ¨ve T cells to differentiate into IL-10-secreting T cells remains a
Figure 5. IL-3 secretion induced by YFAK and YEAK from
splenocytes. Female SJL mice were dosed daily for 5 days with 0.25,
2.5, or 25 mg/kg of YFAK or YEAK. Spleens were collected after a one
week resting period. Splenocytes were re-stimulated for 3 days with
5 mg/mL copolymer. Splenocytes harvested from Vehicle-treated mice
and stimulated with YFAK or YEAK had no detectable level of IL-3. Mean
(pg/mL) 6 SEM of IL-3 is shown. No significant difference in the release
of IL-3 in splenocytes re-stimulated with YFAK or YEAK was evident.
doi:10.1371/journal.pone.0026274.g005
Table 1. Molecular Properties of YFAK and YEAK.
YFAK YEAK
Synthesis Solid Phase Solution Phase
Amino Acid Input YFAK (Tyrosine 1.0, Phenylalanine 1.2,
Alanine 23.5, Lysine 6.0)
YEAK (Tyrosine 1.0, Glutamic Acid 1.5,
Alanine 4.5, Lysine 3.6)
Peptide Charge Strong Net Positive Charge Slightly Net Positive Charge
Molecular Weight Distribution 4–5 kDa 5–9 kDa
Peptide Length 52-mer 20–200-mer
Acetylation N-terminus No
doi:10.1371/journal.pone.0026274.t001
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and IL-3 that stimulate the proliferation and differentiation of M2
macrophages.
The induction of these Tregs by YEAK [24,25] and YFAK
[4,6,26] are both well documented, and the latter have been
extensively characterized. YFAK programs bone marrow progen-
itors to induce a population of CD11b
+/GR-1
high/F4/80
low
macrophages, called myeloid suppressors, that can modulate an
autoimmune response (Figures S1, S2). This phenotype for
myeloid suppressor cells has been reported previously [19,27,28].
Some differences in cytokine/chemokine production were
observed between cells cultured in the presence of YFAK or YEAK
(Figure 4).YFAK significantly increased supernatantconcentrations
of CCL22 (MDC) and of CXCL13 (BCA-1). CCL22 and CXCL13
are chemokines produced by M2 macrophages which areimportant
in the homeostasis of lymphocyte trafficking and are a chemoat-
tractant for T cells and B cells, respectively [15,29]. CCL9 (MIP-
1c), an important chemokine that attracts CD11b
+ DC and myeloid
cells [30], was also increased as a result of YFAK treatment (Figure
S4). Thus, CCL9 may play a role in the attraction/induction of
myeloid suppressor cells which have been shown to be important in
decreasing disease severity [31].
Some data suggest that CCL22 and CXCL13 may be produced
by different cell populations. The serum level of CXCL13 induced
in vivo by YFAK was greater than that of CCL22 (Figures 1 and 2).
However, in vitro the level of CCL22 induced from myeloid
progenitors was 50–100 times that of CXCL13, and YEAK did not
induce CXCL13 from these cells in a detectable amount (Figure 4).
Finally, although both YFAK and YEAK induced CCL22 secretion
from RAW 264.7 murine macrophages (Figure 3), neither
copolymer induced CXCL13 from these cells.
In addition, YFAK significantly decreased the secretion of the
chemokinesCXCL1andCXCL2andofpro-inflammatorycytokines
TNF-a, IL-6, and IL-12p70. The pro-inflammatory properties
associated with TNF-a play a major role in autoimmune diseases
and interference with TNF- a production is a major treatment
modality [32]. Etanercept (EnbrelH), infliximab (RemicadeH), and
adalimumab (HumiraH) are TNF inhibitors that are used in animal
disease models of MS [33] and have been approved for treatment of
patients with rheumatoid arthritis, inflammatory bowel disease, and
psoriasis [34]. IL-12p70 has also been shown to drive a TH1 immune
response [35] and decreasing IL-12p70 production can modulate the
immune response towards a TH2 immune response [36]. Since
modulation of pro-inflammatory cytokines is associated with current
MS treatment [37], this effect of YFAK could directly relate to its
efficacy in EAE. By contrast, YEAK had little or no effect on
secretion of these chemokines and cytokines in various assays.
The relationship between dose of YFAK and efficacy in EAE is
of considerable interest, i.e., 0.75 mg/kg is inefficient at generating
efficacy, 2.5 mg/kg gives significant efficacy, and at 7.5 mg/kg
efficacy is lost. As the dose of YFAK increased, so did activation of
the innate immune response (Figure 4). However, in vitro CCL22
secretion reached a peak of 6 mM and then declined. YEAK,
which is ineffective at low concentration, peaked at 12 mM. If
higher concentrations of YEAK had been used, a decline in
CCL22 secretion may also have been seen. A decline in CCL22
secretion at high YFAK concentrations was also seen in an
additional in vitro assay (N.K., unpublished observation), and was
paralleled in Phase I clinical trials in secondary progressive MS
patients by increased serum concentrations of CCL22, IL-3, and
IL-13 at low dosages followed by decreases at higher dosages [9].
However, as the dose of either copolymer increased, a progressive
loss in IL-3 production from T cells occurred (Figure 5). T cell
activity alone is not solely responsible for efficacy because YFAK
and YEAK would both have similar efficacy and the lower the
dose the higher the T cell activity, i.e., 0.25 mg/kg had more IL-3
production than 2.5 mg/kg. However, 2.5 mg/kg is more
efficacious for therapy. The innate immune response is also not
solely responsible for efficacy. Together these data imply that both
the innate (macrophages) and adaptive (T cells) immune responses
are responsible for efficacy.
Interaction between cells of the innate and adaptive immune
system is quite important in the mechanism. Th17 cells are
believed to play a major role in autoimmune pathologies and
Figure 6. Hypothesis: Role of M2 macrophages in generation of IL-10 secreting T cells. It is not known whether IL-3 is secreted by the
same T cells that secrete IL-4 and IL-13.
doi:10.1371/journal.pone.0026274.g006
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differentiation of Th17 cells through altered production of IL-6 by
monocytes [38]. YFAK reduces IL-6 secretion more severely
(Figure 4) and may effectively control the expansion and
differentiation of Th17 cells. IL-13, a cytokine produced in large
quantity by T cells activated with both YEAK and YFAK, has a
major effect on the differentiation of monocytes [39]. Moreover,
production of IL-13 by these T cells could directly or indirectly
(through antigen-presenting cells) affect the expansion of Th17
cells, since it is known that the IL-13 receptor is expressed by Th17
cells and that IL-13 attenuates Th17 cytokine production [40].
Thus, the optimal dosage requirement for YFAK is one that
strongly stimulates the innate response, yet is low enough to not
abrogate an adaptive immune response.
In summary, chemokine release from myeloid cells, which
occurs rapidly on administration of amino acid copolymers in vivo,
has significant implications for the systemic effect of these
therapeutic agents on both innate and adaptive immunity. The
differential effects of YFAK and YEAK on the innate immune
system may explain the enhanced efficacy of YFAK in the
treatment of EAE and is also likely to lead to better clinical
efficacy.
Supporting Information
Figure S1 CD11b and F4/80 myeloid cell phenotypes
induced from murine bone marrow by YFAK or YEAK.
Flow cytometric analysis was performed to identify phenotypic
populations. (A–E) Data shown represents gating of CD11b versus
F4/80 cell populations. (A–C) Data shown is a representative
sample from cell populations administered 6.0 mM copolymer or
medium control. (D and E) In vitro copolymer concentrations
administered were 1.5, 3.0, and 6.0 mM. Samples were run in
quadruplicate and are shown as percentage of cells 6 SEM.
Significance was calculated using an unpaired t-test: YFAK vs.
YEAK * p#0.05, *** p#0.001. Medium control and PLP 139–
151 produced similar results.
(DOCX)
Figure S2 CD11b and Gr-1 Myeloid cell phenotypes
induced by YFAK or YEAK. Flow cytometric analysis was
performed to identify phenotypic populations. (A–E) Data shown
represents gating of CD11b versus Gr-1 cell populations. (A–C)
Data shown is a representative sample from cell populations
administered 6.0 mM copolymer or medium control. (D and E) In
vitro copolymer concentrations administered were 1.5, 3.0, and
6.0 mM. Samples were run in quadruplicate and are shown as
percentage of cells 6 SEM. Significance was calculated using an
unpaired t-test: YFAK vs. YEAK * p#0.05, ** p#0.01, ***
p#0.001. Medium control and PLP 139–151 produced similar
results.
(DOCX)
Figure S3 Disease progression after daily administra-
tion of YFAK, YEAK, or Vehicle. Female SJL mice were
induced to develop EAE as described in previous publications.
Mice received daily administrations s.c. of 2.5 mg/kg YFAK,
2.5 mg/kg YEAK, or Vehicle beginning after the onset of disease.
Mean 6 SEM of disease progression from initial signs of disease is
shown. Since treatment started after the onset of disease, the graph
shows disease progression in relation to the initial level of disease
(baseline disease) for each mouse. Significance was calculated using
a Mann-Whitney t-test: YFAK vs. YEAK * p#0.05.
(DOCX)
Figure S4 CCL9 (MIP-1c) concentration in culture
supernatant of bone marrow-derived macrophages
stimulated by copolymers.
(DOC)
Table S1 Soluble Factors tested using RBM Rodent
MAP 1.6. The data obtained that are not shown in the text are
available upon request.
(DOCX)
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